JP2021529203A5 - - Google Patents
Info
- Publication number
- JP2021529203A5 JP2021529203A5 JP2020573396A JP2020573396A JP2021529203A5 JP 2021529203 A5 JP2021529203 A5 JP 2021529203A5 JP 2020573396 A JP2020573396 A JP 2020573396A JP 2020573396 A JP2020573396 A JP 2020573396A JP 2021529203 A5 JP2021529203 A5 JP 2021529203A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- compound according
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18181475 | 2018-07-03 | ||
| EP18181475.7 | 2018-07-03 | ||
| PCT/EP2019/067899 WO2020007938A1 (en) | 2018-07-03 | 2019-07-03 | PqsR INVERSE AGONISTS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021529203A JP2021529203A (ja) | 2021-10-28 |
| JP2021529203A5 true JP2021529203A5 (https=) | 2022-07-04 |
| JP7399898B2 JP7399898B2 (ja) | 2023-12-18 |
Family
ID=62846069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020573396A Active JP7399898B2 (ja) | 2018-07-03 | 2019-07-03 | ＰｑｓＲインバースアゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11883387B2 (https=) |
| EP (1) | EP3818045A1 (https=) |
| JP (1) | JP7399898B2 (https=) |
| AU (1) | AU2019297409B2 (https=) |
| CA (1) | CA3103351A1 (https=) |
| WO (1) | WO2020007938A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021136803A1 (en) * | 2020-01-02 | 2021-07-08 | Helmholtz-Zentrum für Infektionsforschung GmbH | NEW PqsR INVERSE AGONISTS |
| WO2021136805A1 (en) * | 2020-01-02 | 2021-07-08 | Helmholtz-Zentrum für Infektionsforschung GmbH | NOVEL PqsR INVERSE AGONISTS |
| WO2024186827A2 (en) * | 2023-03-06 | 2024-09-12 | The Regents Of The University Of California | Novel host-directed therapeutic agent for the treatment of infectious diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2678319B1 (en) | 2011-02-22 | 2019-04-17 | The General Hospital Corporation | Antibiotic tolerance inhibitors |
| WO2014176258A1 (en) | 2013-04-23 | 2014-10-30 | The General Hospital Corporation | Compounds useful as antibiotic tolerance inhibitors |
| WO2016007837A1 (en) | 2014-07-11 | 2016-01-14 | Spero Therapeutics, Inc. | Carbonyl linked bicyclic heteroaryl antibiotic tolerance inhibitors |
| WO2016040764A1 (en) | 2014-09-12 | 2016-03-17 | Spero Therapeutics, Inc. | Carbonyl linked bicyclic heteroaryl n-benzimidazoles and analogs as antibiotic tolerance inhibitors |
| WO2016112088A1 (en) | 2015-01-06 | 2016-07-14 | Spero Therapeutics, Inc. | Aryloxyacetylindoles and analogs as antibiotic tolerance inhibitors |
| US10071988B2 (en) | 2016-02-10 | 2018-09-11 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators |
| CN108003151B (zh) * | 2016-10-27 | 2019-11-05 | 湖南化工研究院有限公司 | N-杂芳基甲基嘧啶胺类化合物及其制备方法与应用 |
-
2019
- 2019-07-03 EP EP19741977.3A patent/EP3818045A1/en active Pending
- 2019-07-03 US US17/257,804 patent/US11883387B2/en active Active
- 2019-07-03 AU AU2019297409A patent/AU2019297409B2/en active Active
- 2019-07-03 JP JP2020573396A patent/JP7399898B2/ja active Active
- 2019-07-03 CA CA3103351A patent/CA3103351A1/en active Pending
- 2019-07-03 WO PCT/EP2019/067899 patent/WO2020007938A1/en not_active Ceased